# A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

> **NCT02053454** · PHASE1 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Transthyretin (TTR)-Mediated Amyloidosis

## Interventions

- **DRUG:** patisiran (ALN-TTR02)
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT02053454
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-03
- **Final completion:** 2014-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02053454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02053454, "A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02053454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*